“Bimekizumab Rates of Oral Candidiasis in Patients With Moderate to Severe Plaque Psoriasis: Results from up to 4 Years of Five Phase 3 3b Studies”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s646, https://doi.org/10.25251/ta5v8k92.